|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Peugeot_vehicles
|
|
gptkbp:acquisition
|
Forte Biosciences (2020)
Gelesis (2018)
Karuna Therapeutics (2018)
Vedanta Biosciences (2021)
|
|
gptkbp:ceo
|
gptkb:Daphne_Koller
|
|
gptkbp:collaborations
|
gptkb:University
gptkb:Duke_University
gptkb:Harvard_University
gptkb:Johns_Hopkins_University
gptkb:Stanford_University
gptkb:University_of_California,_San_Francisco
gptkb:University_of_Pennsylvania
gptkb:Massachusetts_General_Hospital
gptkb:MIT
gptkb:Brigham_and_Women's_Hospital
|
|
gptkbp:employees
|
200+
|
|
gptkbp:focus
|
gptkb:Company
|
|
gptkbp:founded
|
gptkb:2008
|
|
gptkbp:founder
|
gptkb:Daphne_Koller
|
|
gptkbp:headquarters
|
gptkb:Boston,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pure Tech
|
|
gptkbp:investment
|
healthcare
$500 million (2021)
$300 million (2020)
$200 million (2019)
$100 million (2018)
$10 million (2015)
$50 million (2017)
$1 million (2013)
$25 million (2016)
$5 million (2014)
$500,000 (2012)
|
|
gptkbp:ipo
|
gptkb:2015
|
|
gptkbp:mission
|
transforming the treatment of disease
|
|
gptkbp:partnership
|
gptkb:temple
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Novartis
|
|
gptkbp:research_focus
|
gptkb:healthcare_organization
gptkb:psychologist
metabolic diseases
immune-mediated diseases
|
|
gptkbp:revenue
|
$100 million (2022)
|
|
gptkbp:subsidiary
|
Vedanta Biosciences
Forte Biosciences
Karuna Therapeutics
Gelesis
|
|
gptkbp:symbol
|
PRTC
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:Company
|
|
gptkbp:website
|
www.puretechhealth.com
|